Acetylcysteine/bethanechol chloride

Drug Profile

Acetylcysteine/bethanechol chloride

Alternative Names: Bethanechol chloride/acetylcysteine; DM-71

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator DiaMedica
  • Developer DiaMedica Therapeutics
  • Class Antihyperglycaemics; Reducing agents; Small molecules; Sulfur amino acids; Trimethyl ammonium compounds
  • Mechanism of Action Adrenergic receptor agonists; Antioxidants; Cholinergic receptor agonists; Free radical inhibitors; Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 29 Dec 2016 DiaMedica is now called DiaMedica Therapeutics
  • 01 Dec 2016 Unknown biopharmaceutical company acquires Acetylcysteine/bethanechol-chloride from DiaMedica
  • 27 Oct 2010 Phase II development has been completed in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top